Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma

Thrombosis and Haemostasis

Volumn 104, Issue 1, 2010, Pages 157-164

  Johansen, Peter B ^a   Bjørn, Søren E ^a   Agersø, Henrik ^a   Thorup, Inger ^a   Hermit, Mette B ^a   Sørensen, Brit B ^a   Stennicke, Henning R ^a   Ezban, Mirella ^a   Tranholm, Mikael ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Coagulation activity; glycoPEGylated rFVIIa; Rabbits; Venous stasis

Indexed keywords

40K POLYETHYLENE GLYCOL RECOMBINANT FACTOR VIIA; BIOLOGICAL MARKER; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOT; BLOOD CLOTTING; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG HALF LIFE; FEMALE; HUMAN; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RABBIT; WILD TYPE;

ANIMALS; BLOOD COAGULATION DISORDERS; BLOOD PROTEINS; COAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIIA; FEMALE; GLYCOSYLATION; HUMANS; MODELS, ANIMAL; POLYETHYLENE GLYCOLS; POSTTHROMBOTIC SYNDROME; PROTEIN STABILITY; RABBITS; RECOMBINANT PROTEINS;

EID: 77954368872     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-11-0797     Document Type: Article

References (23)

1. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-1913. (Pubitemid 47288949)
2. Weimer T, Ostergaard H, Bayer RJ, et al. Prolonged in-vivo half-life of factor VIIa derivatives. Thromb Haemost 2008; 99: 659-667. (Pubitemid 351694221)
3. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002; 54: 459-476.
4. Wessler S. Studies in intravascular coagulation. I. Coagulation changes in isolated venous segments. J Clin Invest 1952; 31: 1011-1014.
5. Peternel L, Drevensek G, Cerne M, et al. Evaluation of two experimental venous thrombosis models in the rat. Thromb Res 2005; 115: 527-534. (Pubitemid 40409987)
6. Matthiasson SE, Lindblad B, Matzsch T, et al. Effect of low molecular weight heparin, dextran and their combinations on experimental venous thrombosis in rabbits. Thromb Haemost 1994; 71: 363-365. (Pubitemid 24083749)
7. Diness V, Bregengaard C, Erhardtsen E, et al. Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thromb Res 1992; 67: 233-241.
8. Morrissey JH, Macik BG, Neuenschwander PF, et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744.
9. Wildgoose P, Nemerson Y, Hansen LL, et al. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992; 80: 25-28.
10. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-anti-thrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-106. (Pubitemid 18053658)
11. Tranholm M, Kristensen K, Kristensen AT, et al. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 2003; 102: 3615-3620. (Pubitemid 37409379)
12. Lauritzen B, Tranholm M, Ezban M. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. J Thromb Haemost 2009; 7: 651-657.
13. Tranholm M, Rojkjaer R, Pyke C, et al. Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits. Thromb Res 2003; 109: 217-223. (Pubitemid 36712911)
14. Sørensen BB, Karpf D, Groth AV, Bysted BV, Hermit MB, Tranholm M et al. Effect of Glycopegylation on the pharmacokinetic properties of FVIIa. J Thromb Haemost 2007; 5 (Suppl 2): Abstract P-T-012.
15. Fridberg MJ, Hedner U, Roberts HR, et al. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis 2005; 16: 259-266. (Pubitemid 40705047)
16. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 2000; 26: 385-391.
17. Møss J, Rosholm A, Laurén A. Safety and pharmacokinetics of a long-acting glycopegylated rFVIIa derivative: A first human dose trial in healthy subjects. J Thromb Haemost 2009; 7 (Suppl 2): Abstract OC-WE-055.
18. Hoffman M, Monroe DM, III, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl 1): S61-S65. (Pubitemid 28511567)
19. Østerud B, Breimo ES, Olsen JO. Blood borne tissue factor revisited. Thromb Res 2008; 122: 432-434.
20. Taylor FB, Jr., Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-1330.
21. Berthelsen LO, Kristensen AT, Wiinberg B, et al. Implementation of the ISTH classification of non-overt DIC in a thromboplastin induced rabbit model. Thromb Res 2009; 124: 490-497.
22. Roberts HR, Monroe DM, III, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41: 101-108. (Pubitemid 38182725)
23. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008; 14: 898-902.